Evidence map›Paper›PMID 25343517›Full record

ArticlePloS one2014

Lack of involvement of CEP adducts in TLR activation and in angiogenesis.

John Gounarides, Jennifer S Cobb, Jing Zhou, Frank Cook, Xuemei Yang, Hong Yin, Erik Meredith, Chang Rao, Qian Huang, YongYao Xu and 17 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Biological and pathophysiological roles of end-products of DHA oxidation.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors at 2 institutions in 1 country.

John GounaridesAnalytical Sciences, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Jennifer S CobbAnalytical Sciences, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Jing ZhouAnalytical Sciences, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Frank CookAnalytical Sciences, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Xuemei YangAnalytical Sciences, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Hong YinAnalytical Sciences, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Erik MeredithGlobal Discovery Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Chang RaoAnalytical Sciences, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Qian HuangDevelopmental and Metabolic Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
YongYao XuDevelopmental and Metabolic Pathways, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Karen AndersonOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Andrea De ErkenezOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Sha-Mei LiaoOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Maura CrowleyOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Natasha BuchananOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Stephen PoorOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Yubin QiuOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Elizabeth FassbenderOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Siyuan ShenOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Amber WoolfendenOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Amy JensenOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Rosemarie CepedaOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Bijan Etemad-GilbertsonOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Shelby GizaOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Muneto MogiGlobal Discovery Chemistry, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Bruce JaffeeOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Sassan AzarianOphthalmology, Novartis Institutes for Biomedical Research, Cambridge, MA, United States of America.
Novartis (United States) · USPathways Behavioral Services · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proteins that are post-translationally adducted with 2-(ω-carboxyethyl)pyrrole (CEP) have been proposed to play a pathogenic role in age-related macular degeneration, by inducing angiogenesis in a Toll Like Receptor 2 (TLR2)-dependent manner. We have investigated the involvement of CEP adducts in angiogenesis and TLR activation, to assess the therapeutic potential of inhibiting CEP adducts and TLR2 for ocular angiogenesis. As tool reagents, several CEP-adducted proteins and peptides were synthetically generated by published methodology and adduction was confirmed by NMR and LC-MS/MS analyses. Structural studies showed significant changes in secondary structure in CEP-adducted proteins but not the untreated proteins. Similar structural changes were also observed in the treated unadducted proteins, which were treated by the same adduction method except for one critical step required to form the CEP group. Thus some structural changes were unrelated to CEP groups and were artificially induced by the synthesis method. In biological studies, the CEP-adducted proteins and peptides failed to activate TLR2 in cell-based assays and in an in vivo TLR2-mediated retinal leukocyte infiltration model. Neither CEP adducts nor TLR agonists were able to induce angiogenesis in a tube formation assay. In vivo, treatment of animals with CEP-adducted protein had no effect on laser-induced choroidal neovascularization. Furthermore, in vivo inactivation of TLR2 by deficiency in Myeloid Differentiation factor 88 (Myd88) had no effect on abrasion-induced corneal neovascularization. Thus the CEP-TLR2 axis, which is implicated in other wound angiogenesis models, does not appear to play a pathological role in a corneal wound angiogenesis model. Collectively, our data do not support the mechanism of action of CEP adducts in TLR2-mediated angiogenesis proposed by others.

Indexed as

AnimalsChoroidal NeovascularizationDisease Models, AnimalHEK293 CellsHumansLasersLeukocytesMice, Inbred C57BLNeovascularization, PathologicPyrrolesRetinaToll-Like Receptor 22-(omega-carboxyethyl)pyrrolePyrrolesToll-Like Receptor 2

Identifiers

PMID25343517
PMCPMC4208838
OpenAlexW1989610499

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.